“I don’t see this CEO getting sidetracked by a disease du jour like our last one.”

I completely agree. While Dr Jay is CEO and all that implies, anyone that has heard him speak comprehends that he is a clinician whose first instincts are toward compassion, empathy and healing and they are paramount. His first priority is to get Leronlimab in the hands of doctors who can do good with it. His stated priority of MSS CRC underscores the strategy to get there as success in that indication will put Leronlimab solidly on a path toward approval. I will repeat myself here, this strategy could well involve breakthrough therapy designation which implies additional dedicated assistance from the FDA to break down barriers which can impede progress to market.